|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merika E, Saif MW, Katz A, Syrigos K and
Morse M: Review. Colon cancer vaccines: An update. In Vivo.
24:607–628. 2010.PubMed/NCBI
|
|
4
|
Lee YT: Local and regional recurrence of
carcinoma of the colon and rectum: I. Tumour-host factors and
adjuvant therapy. Surg Oncol. 4:283–293. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Declan Fleming RY: Colorectal cancer
screening and follow-up. Surg Oncol. 7:125–137. 1998. View Article : Google Scholar
|
|
6
|
Figueredo A, Rumble RB, Maroun J, Earle
CC, Cummings B, McLeod R, Zuraw L and Zwaal C; Gastrointestinal
Cancer Disease Site Group of Cancer Care Ontario's Program in
Evidence-based Care. Follow-up of patients with curatively resected
colorectal cancer: A practice guideline. BMC Cancer. 3:262003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chambers WM and Mortensen NJ:
Postoperative leakage and abscess formation after colorectal
surgery. Best Pract Res Clin Gastroenterol. 18:865–880. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carmena M and Earnshaw WC: The cellular
geography of aurora kinases. Nat Rev Mol Cell Biol. 4:842–854.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nigg EA: Mitotic kinases as regulators of
cell division and its checkpoints. Nat Rev Mol Cell Biol. 2:21–32.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirota T, Kunitoku N, Sasayama T, Marumoto
T, Zhang D, Nitta M, Hatakeyama K and Saya H: Aurora-A and an
interacting activator, the LIM protein Ajuba, are required for
mitotic commitment in human cells. Cell. 114:585–598. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Zhu J, Firozi PF, Abbruzzese JL,
Evans DB, Cleary K, Friess H and Sen S: Overexpression of oncogenic
STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer
Res. 9:991–997. 2003.PubMed/NCBI
|
|
12
|
Matarasso N, Bar-Shira A, Rozovski U,
Rosner S and Orr-Urtreger A: Functional analysis of the Aurora
Kinase A Ile31 allelic variant in human prostate. Neoplasia.
9:707–715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamamoto S, Yamamoto-Ibusuki M, Yamamoto
Y, Fujiwara S and Iwase H: A comprehensive analysis of Aurora A;
transcript levels are the most reliable in association with
proliferation and prognosis in breast cancer. BMC Cancer.
13:2172013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aust DE, Muders M, Köhler A, Schmidt M,
Diebold J, Müller C, Löhrs U, Waldman FM and Baretton GB:
Prognostic relevance of 20q13 gains in sporadic colorectal cancers:
A FISH analysis. Scand J Gastroenterol. 39:766–772. 2004.
View Article : Google Scholar
|
|
15
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et
al: A homologue of Drosophila aurora kinase is oncogenic and
amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carvalho B, Postma C, Mongera S, Hopmans
E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A,
Cuesta MA, et al: Multiple putative oncogenes at the chromosome 20q
amplicon contribute to colorectal adenoma to carcinoma progression.
Gut. 58:79–89. 2009. View Article : Google Scholar
|
|
17
|
Goos JA, Coupe VM, Diosdado B, Delis-Van
Diemen PM, Karga C, Beliën JA, Carvalho B, van den Tol MP, Verheul
HM, Geldof AA, et al; DeCoDe PET group. Aurora kinase A (AURKA)
expression in colorectal cancer liver metastasis is associated with
poor prognosis. Br J Cancer. 109:2445–2452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hermsen M, Postma C, Baak J, Weiss M,
Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W,
et al: Colorectal adenoma to carcinoma progression follows multiple
pathways of chromosomal instability. Gastroenterology.
123:1109–1119. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakao K, Mehta KR, Fridlyand J, Moore DH,
Jain AN, Lafuente A, Wiencke JW, Terdiman JP and Waldman FM:
High-resolution analysis of DNA copy number alterations in
colorectal cancer by array-based comparative genomic hybridization.
Carcinogenesis. 25:1345–1357. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Postma C, Terwischa S, Hermsen MA, van der
Sijp JR and Meijer GA: Gain of chromosome 20q is an indicator of
poor prognosis in colorectal cancer. Cell Oncol. 29:73–75.
2007.PubMed/NCBI
|
|
21
|
Sillars-Hardebol AH, Carvalho B, de Wit M,
Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van de Wiel MA,
Meijer GA and Fijneman RJ: Identification of key genes for
carcinogenic pathways associated with colorectal
adenoma-to-carcinoma progression. Tumour Biol. 31:89–96. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerlach U, Kayser G, Walch A, Hopt U,
Schulte-Mönting J, Werner M and Lassmann S: Centrosome-,
chromosomal-passenger- and cell-cycle-associated mRNAs are
differentially regulated in the development of sporadic colorectal
cancer. J Pathol. 208:462–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lam AK, Ong K and Ho YH: Aurora kinase
expression in colorectal adenocarcinoma: Correlations with
clinicopathological features, p16 expression, and telomerase
activity. Hum Pathol. 39:599–604. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dar AA, Goff LW, Majid S, Berlin J and
El-Rifai W: Aurora kinase inhibitors - rising stars in cancer
therapeutics? Mol Cancer Ther. 9:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Görgün G, Calabrese E, Hideshima T, Ecsedy
J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, et al: A
novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and
cell-cycle arrest in multiple myeloma. Blood. 115:5202–5213. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng TO: Cardiovascular effects of
Danshen. Int J Cardiol. 121:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gong Y, Li Y, Abdolmaleky HM, Li L and
Zhou JR: Tanshinones inhibit the growth of breast cancer cells
through epigenetic modification of Aurora A expression and
function. PLoS One. 7:e336562012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nizamutdinova IT, Lee GW, Lee JS, Cho MK,
Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, et al: Tanshinone
I suppresses growth and invasion of human breast cancer cells,
MDA-MB-231, through regulation of adhesion molecules.
Carcinogenesis. 29:1885–1892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee CY, Sher HF, Chen HW, Liu CC, Chen CH,
Lin CS, Yang PC, Tsay HS and Chen JJ: Anticancer effects of
tanshinone I in human non-small cell lung cancer. Mol Cancer Ther.
7:3527–3538. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Katayama H, Sasai K, Kawai H, Yuan ZM,
Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA and Sen
S: Phosphorylation by aurora kinase A induces Mdm2-mediated
destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.
|
|
32
|
Giet R and Prigent C: Aurora/Ipl1p-related
kinases, a new oncogenic family of mitotic serine-threonine
kinases. J Cell Sci. 112:3591–3601. 1999.PubMed/NCBI
|
|
33
|
Kaestner P, Stolz A and Bastians H:
Determinants for the efficiency of anticancer drugs targeting
either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Mol Cancer Ther. 8:2046–2056. 2009. View Article : Google Scholar
|
|
34
|
Vankayalapati H, Bearss DJ, Saldanha JW,
Muñoz RM, Rojanala S, Von Hoff DD and Mahadevan D: Targeting
aurora2 kinase in oncogenesis: A structural bioinformatics approach
to target validation and rational drug design. Mol Cancer Ther.
2:283–294. 2003.PubMed/NCBI
|
|
35
|
Baba Y, Nosho K, Shima K, Irahara N, Kure
S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS and Ogino S: Aurora-A
expression is independently associated with chromosomal instability
in colorectal cancer. Neoplasia. 11:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng
J, Sun J and Yang G: Aurora-A: A potential DNA repair modulator.
Tumour Biol. 35:2831–2836. 2014. View Article : Google Scholar
|
|
37
|
Hu W, Kavanagh JJ, Deaver M, Johnston DA,
Freedman RS, Verschraegen CF and Sen S: Frequent overexpression of
STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell
cultures derived from human ovarian cancer. Oncol Res. 15:49–57.
2005.PubMed/NCBI
|
|
38
|
Liu Q, Kaneko S, Yang L, Feldman RI,
Nicosia SV, Chen J and Cheng JQ: Aurora-A abrogation of p53 DNA
binding and trans-activation activity by phosphorylation of serine
215. J Biol Chem. 279:52175–52182. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nair JS, Ho AL and Schwartz GK: The
induction of polyploidy or apoptosis by the Aurora A kinase
inhibitor MK8745 is p53-dependent. Cell Cycle. 11:807–817. 2012.
View Article : Google Scholar :
|
|
40
|
Liu MC and Gelmann EP: P53 gene mutations:
Case study of a clinical marker for solid tumors. Semin Oncol.
29:246–257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006. View Article : Google Scholar
|
|
42
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligo-nucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.PubMed/NCBI
|
